Bevacizumab全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球Bevacizumab市場預計將從2025年的76.6億美元成長至2034年的184.6億美元，2026年至2034年的複合年成長率（CAGR）為10.26%。該市場正經歷顯著成長，主要受癌症發病率上升和標靶治療需求成長的推動。Bevacizumab是一種單株抗體，用於治療多種癌症，包括大腸癌、肺癌和乳癌。它能夠抑制血管生成——即為腫瘤提供營養的新血管的形成——這使得Bevacizumab成為腫瘤治療的重要組成部分。對個人化醫療和先進癌症治療的日益重視也進一步推動了市場需求。

關鍵促進因素包括生物技術的進步以及對癌症研發投入的增加。生物相似藥的日益普及也促進了市場擴張，因為它提高了治療的可及性和成本效益。此外，醫療基礎設施和診斷能力的提升使得癌症的早期發現和治療成為可能，從而增加了Bevacizumab的使用。政府對癌症治療計畫的扶持和資金投入也進一步推動了市場成長。

展望未來，持續的研發投入和新療法的開發有望推動市場成長。生物相似藥的推廣將提高患者的用藥可及性並降低治療成本。新興市場由於醫療保健投入的增加和公眾意識的提高，預計將實現顯著成長。隨著全球癌症負擔的持續加重，Bevacizumab市場將在推動癌症治療和改善患者預後方面發揮關鍵作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為了解競爭趨勢和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點，或針對特定細分市場的深入洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球Bevacizumab市場：依產品分類

• 市場分析、洞察與預測
• Avastin
• Alymsys
• Mvasi
• 其他

第5章 全球Bevacizumab市場：依適應症分類

• 市場分析、洞察與預測
• 轉移性大腸直腸癌
• 復發性膠質母細胞瘤
• 轉移性腎細胞癌
• 持續性、復發性或轉移性子宮頸癌
• 其他

第6章 全球Bevacizumab市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥局和藥房
• 其他

第7章 全球Bevacizumab市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Genentech Inc.（F. Hoffmann-La Roche Ltd）
  • Pfizer Inc
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Amgen Inc
  • Celltrion Healthcare Co. Ltd

The global bevacizumab market size is expected to reach USD 18.46 Billion in 2034 from USD 7.66 Billion in 2025, growing at a CAGR of 10.26 during 2026-2034.This market is experiencing significant growth driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Bevacizumab is a monoclonal antibody used in the treatment of various cancers, including colorectal, lung, and breast cancer. Its ability to inhibit angiogenesis, the formation of new blood vessels that feed tumors, has made it a crucial component in oncology treatment. The growing focus on personalized medicine and advanced cancer therapies is further boosting market demand.

Key drivers include advancements in biotechnology and increasing investments in cancer research and development. The rising adoption of biosimilars is also contributing to market expansion by making treatments more accessible and affordable. Additionally, the growing healthcare infrastructure and improved diagnostic capabilities are enabling early detection and treatment of cancer, increasing the use of bevacizumab. Government initiatives and funding for cancer treatment programs are further supporting market growth.

Looking ahead, the market is expected to benefit from ongoing research and the development of new therapeutic applications. The expansion of biosimilar products will enhance accessibility and reduce treatment costs. Emerging markets are anticipated to witness significant growth due to increasing healthcare investments and awareness. As the global burden of cancer continues to rise, the bevacizumab market is set to play a critical role in advancing oncology treatment and improving patient outcomes.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Avastin
• Alymsys
• Mvasi
• Others

By Indication

• Metastatic Colorectal Cancer
• Recurrent Glioblastoma
• Metastatic Renal Cell Carcinoma
• Persistent, Recurrent, or Metastatic Cervical Cancer
• Others

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies and Drug Stores
• Others

COMPANIES PROFILED

• Genentech Inc. (F. Hoffmann-La Roche Ltd), Pfizer Inc., Amneal Pharmaceuticals LLC., Novartis AG, Amgen Inc., Celltrion Healthcare Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BEVACIZUMAB MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Avastin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Alymsys Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Mvasi Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BEVACIZUMAB MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Metastatic Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Recurrent Glioblastoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metastatic Renal Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Persistent, Recurrent, or Metastatic Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BEVACIZUMAB MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channels
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies and Drug Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BEVACIZUMAB MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channels
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channels
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channels
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channels
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channels
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BEVACIZUMAB INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc. (F. Hoffmann-La Roche Ltd)
  • 9.2.2 Pfizer Inc
  • 9.2.3 Amneal Pharmaceuticals LLC
  • 9.2.4 Novartis AG
  • 9.2.5 Amgen Inc
  • 9.2.6 Celltrion Healthcare Co. Ltd